News
IDIBELL receives a grant from the Generalitat to promote Personalized Medicine on campus
The Generalitat of Catalonia has awarded IDIBELL a co-financed project of 2 million euros that will consolidate Personalized Medicine on the Bellvitge campus. The money will be used to create and improve infrastructures that allow the management and storage of patient samples and derived data, ensuring their integrity and traceability.
Identified new susceptibility genes to inflammatory bowel diseases
A study led by IDIBELL and the ICO has analyzed genetic data from thousands of patients with inflammatory bowel disease through an innovative statistical approach that has made it possible to identify new susceptibility genes to this disease.
Light-activated drugs, localized medicine without side effects
A team from IDIBELL and the University of Barcelona has devised two treatments based on this innovative technology: a derivative of morphine that does not generate addition, a new treatment against psoriasis. Also they used this technology to determine the adenosine role in pain transmission.
A natural compound designated as an orphan drug for cystinuria
Cystinuria is a rare disease characterized by the formation of cystine stones in the kidney and urinary tract. This compound could prevent or delay the appearance of cystine stones.
Lung transplantation is effective for pulmonary fibrosis patients with short telomeres
The study shows that one-year survival after transplantation is greater than 80% regardless of whether there was telomere dysfunction.
Multidisciplinary care increases the quality of life and survival of ALS patients
The results of a study carried out by Dr. Mónica Povedano, principal investigator at IDIBELL, reinforce the value of centralized care for the disease
Aging of the hematopoietic stem cell niche
M. Carolina Florian, head of the Stem Cell Aging group, to present new research in the biology of aging at the world’s largest aging research for drug discovery conference
The Spanish State at the forefront of Europe in young waterpipe tobacco smokers
A study in which IDIBELL and ICO professionals have participated confirms that 90% of electronic cigarette smokers also consume conventional cigarettes and warns that social networks are becoming a channel of promotion, covertly or indirectly, of tobacco products banned by the European Tobacco Products Directive (TPD).